My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC - Episode 4
Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.